Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.

about

Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

P2860

Q58763923-4FBF1EF3-928A-4227-8E6C-5E4D716F72A8

P2860

Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.

Item

http://www.wikidata.org/entity/Q48332605

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pharmacodynamics and pharmacok ...... es and chronic kidney disease.

@en

Pharmacodynamics and pharmacok ...... es and chronic kidney disease.

@nl

type

Item

label

Pharmacodynamics and pharmacok ...... es and chronic kidney disease.

@en

Pharmacodynamics and pharmacok ...... es and chronic kidney disease.

@nl

prefLabel

Pharmacodynamics and pharmacok ...... es and chronic kidney disease.

@en

Pharmacodynamics and pharmacok ...... es and chronic kidney disease.

@nl

P1476

Pharmacodynamics and pharmacok ...... mes and chronic kidney disease

@en

P2093

Chao Li

http://www.w3.org/2001/XMLSchema#string

Jing Li

http://www.w3.org/2001/XMLSchema#string

Jing Qi

http://www.w3.org/2001/XMLSchema#string

Yaling Han

http://www.w3.org/2001/XMLSchema#string

Yi Li

http://www.w3.org/2001/XMLSchema#string

Yunbiao Tang

http://www.w3.org/2001/XMLSchema#string

P2860

The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.

Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry.

A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease.

A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma

Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.

Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist

Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.

Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting.

Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.

P304

88-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.13436

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Heyang Wang

P577

2017-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28921624

http://www.w3.org/2001/XMLSchema#string

P921

clopidogrel

P932

5736840

http://www.w3.org/2001/XMLSchema#string

Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.

about

P2860

P2860

Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932